A 47-year-old woman with idiopathic pulmonary arterial hypertension (IPAH) was referred to our hospital for treatment of an ovarian tumor. Although chest contrast-enhanced CT scans obtained on admission revealed pulmonary arterial thrombosis, she was diagnosed with IPAH with central pulmonary thrombosis based on a normal perfusion lung scan. We initiated upfront triple combination therapy with pulmonary vasodilators. After one month of the therapy, the patient's pulmonary hemodynamics improved. Gynecological surgery was performed under general anesthesia without any perioperative complications. Providing careful intensive management of patients with severe PAH can reduce the perioperative risks of non-cardiac and nonobstetric surgery.
Introduction
Patients with pulmonary arterial hypertension (PAH) are at high risk of suffering from vascular and thrombotic complications during perioperative management for non-cardiac surgery (1) (2) (3) (4) (5) (6) . However, when pulmonary hypertension is well-controlled with appropriate treatment, the perioperative morbidity and mortality of PAH patients who undergo noncardiac and non-obstetric elective operations decrease (6) . We herein report a case of idiopathic PAH (IPAH) with central pulmonary thrombosis that was distinguished from chronic thromboembolic pulmonary arterial hypertension (CTEPH) based on a normal perfusion lung scan in a patient who underwent gynecological surgery. Although the degree of pulmonary hypertension before the surgery was severe, no major perioperative complications were observed due to the strict regulation of hemodynamics provided by using upfront triple combination therapy targeting the prostacyclin, endothelin and nitric oxide pathways in preparation for gynecological surgery under general anesthesia.
Case Report
A 47-year-old woman had been diagnosed with IPAH seventeen years earlier at another hospital after developing hemoptysis during pregnancy. At that time, the estimated mean pulmonary artery pressure (PAP) on cardiac ultrasonography was 60 mmHg, while right heart catheterization (RHC) showed a PAP of 81/34 mmHg (mean, 51 mmHg), a wedge pressure of 4 mmHg and a cardiac index (CI) of 3.40 L/min/m 2 . A diagnosis of secondary pulmonary hypertension (PH) due to pulmonary thromboembolism was ruled out based on the absence of thrombosis on contrast-enhanced CT scanning and normal perfusion lung scan findings. After receiving an abortion, the patient was treated with long-term oxygen therapy and diuretics. Following the initiation of treatment, her symptoms improved, with only slight dyspnea on exertion, although the PAP on cardiac ultrasonography remained unchanged. Three months before admission to our hospital, the patient presented with repeated hemoptysis. A contrastenhanced CT scan revealed intramural thrombi in the central pulmonary arteries with growth of bilateral ovarian cysts, which had been previously detected. The anticoagulant therapy was withheld due to the risk of hemoptysis. On the other hand, since the ovarian cysts had the potential to be malignant, surgical treatment was recommended. Therefore, she was referred to our hospital for management of the ovarian tumors and IPAH.
The patient's height and weight were 168 cm and 55.4 kg, respectively. A physical examination revealed a body temperature of 36.5 , a blood pressure of 119/78 mmHg, a heart rate of 96 beats/min, an SpO2 of 95% on room air and a respiratory rate of 13 breaths/min. The WHO functional assessment classification was class II. The laboratory findings on admission showed a high brain natriuretic peptide (BNP) level of 46.5 pg/mL, with a d-dimer level of 4.8 μg/ mL. The results of an arterial blood gas analysis on room air revealed a PaO2 of 76 Torr (Table 1) . A radiograph of the chest showed dilated central pulmonary arteries, with a cardiothoracic ratio of 40% ( Fig. 1A) . A pulmonary spirometry evaluation indicated mild obstructive abnormalities and a low diffusing capacity for carbon dioxide (Table 1 ). An electrocardiogram suggested right heart overload ( Fig. 1B) , while cardiac ultrasonography demonstrated enlargement of the right atrium and ventricle, ventricular septal deviation to the left and systolic tricuspid regurgitation with a pressure gradient of 48 mmHg. Contrast-enhanced CT scans showed intramural severe thrombi in both the main pulmonary arteries, without any mosaic patterns of lung attenuation (Fig. 2 ). In addition, the bilateral common iliac veins were compressed by bilateral ovarian tumors (right/left 75×35/70×30 mm, respectively), and the presence of both a uterine myoma and bilateral femoral vein thrombi was observed. Despite the existence of deep venous thrombosis (DVT), perfusion lung scans demonstrated no segmental or larger perfusion defects, with normal ventilation scans, regardless of the obvious pulmonary thrombi ( Fig. 3 ). Although the possibility of CTEPH was considered based on the findings of the CT scans, the patient was diagnosed with IPAH complicated with central thrombosis due to the lack of any obvious areas of mismatch on the ventilation-perfusion lung scans. Anticoagulant therapy with warfarin was started for the deep vein thrombosis associated with the ovarian tumors. Furthermore, RHC was conducted to evaluate the severity of the pulmonary arterial hypertension. The RHC revealed a PAP of 61/42 (mean, 51) mmHg, a CI of 1.58 L/ min/m 2 and a calculated pulmonary vascular resistance (PVR) of 1,460 dyn.s.cm -5 .
Because poorly controlled PAH is associated with high morbidity and mortality rates during the perioperative period for surgical treatment of ovarian tumors and providing maximum treatment for severe PAH associated with a low CI and high PVR before surgery is necessary, we decided to administer upfront combination therapy targeting three different pathways. Treatment with bosentan was started on the day after RHC, and treatment with tadalafil was started four days thereafter. Furthermore, a continuous intravenous infusion of epoprostenol was introduced eight days after starting tadalafil, and the dose of epoprostenol was gradually increased to 15.0 ng/min/kg. We again performed contrastenhanced CT and RHC one month after the initiation of these treatments, because deferring surgery for over one month could potentially result in a missed opportunity to administer radical therapy for the ovarian tumors if such tumors were later found to exhibit high-grade malignancy. A reevaluation of the contrast-enhanced CT scans demonstrated that the pulmonary thrombosis had remained unchanged in spite of the administration of anticoagulant therapy. However, in the repeated RHC study performed on the 29th day after starting the continuous intravenous epoprostenol infusion, the CI and PVR had markedly improved from 1.58 to 2.78 L/min/m 2 and from 1,460 to 843 dyn.s. cm -5 , respectively, although the PAP had increased slightly from 61/42 (mean, 51) to 83/31 (mean, 54) mmHg ( Table 2 ). On the day after the second RHC, the patient underwent bilateral salpingo-oophorectomy with hysterectomy and partial omentectomy under general anesthesia. The operative time was four hours and five minutes, and the total amount of blood loss was 500 mL. There were no major complications during the perioperative period. She did not wish to receive continuous intravenous epoprostenol at home due to the drug's complex delivery system and side effects, such as depression. The dose of epoprostenol was therefore decreased gradually, then stopped completely on the 27th day after the surgery. The patient was discharged from our hospital soon after we started the beraprost therapy, simultaneously with the discontinuation of epoprostenol. The pathology of the ovarian tumors revealed a mixed mullerian borderline tumor associated with endometriosis.
On the third RHC study performed three months after discharge, the PAP and PVR had improved from 83/31 (mean, 54) to 51/19 (mean, 36) mmHg and from 843 to 670 dyn.s. cm -5 , respectively, although the CI had decreased from 2.78 to 2.10 L/min/m 2 ( Table 2) . We decided to continue the treatment with oral combination therapy using bosentan, tadalafil and beraprost, because the patient continued to refuse epoprostenol therapy, and her 6-minute walk distance was fair (480 m), with a New York Heart Association class II status.
Discussion
We diagnosed the present patient with IPAH complicated with central thrombosis that was distinguished from CTEPH based on normal perfusion lung scans, although thrombosis was observed in the main pulmonary arteries. IPAH and CTEPH must be differentiated prior to selecting the treatment, because different therapeutic strategies are recommended for these conditions. In particular, the central type of CTEPH can be expected to be associated with an improvement in the prognosis following pulmonary endarterectomy. Moser and colleagues reported that the finding of no segmental or larger defects on a perfusion scan can be used to distinguish PAH from CTEPH without the need for confirmatory pulmonary angiography (7) . To the best of our knowledge, IPAH complicated with central thrombosis is comparatively rare, with only two case reports having been published to date (7, 8) . In these reports, the thrombi in the central pulmonary arteries were considered to have engrafted upon intimal injuries induced by long-standing pulmonary hypertension, developing in situ. In patients with Eisenmenger syndrome, Broberg et al. showed that a decreased pulmonary flow velocity causes thrombosis in the pulmonary artery (9). Reiter et al. reported that the vortices of the blood flow in the main pulmonary artery thus make it possible to identify pulmonary hypertension (10) . In the present case, we suppose that the thrombi were formed partly as a result of the long-term exposure to a high pulmonary blood pressure and/or complex turbulent field in the main trunk of the pulmonary artery, although most IPAH patients do not exhibit central thrombosis. The exact reasons as to why this patient survived under a treatment regimen of only diuretics and oxygen therapy for 17 years after the diagnosis of IPAH remain unclear. However, we believe that this case is an example of "idiopathic" PAH based on the absence of any underlying etiology of PAH, such as congestive heart disease or portal hypertension. The use of general anesthesia and major surgery is associated with a significant risk of worsening right heart failure in PAH patients, which can result in pulmonary hypertensive crisis due to a systemic inflammatory response and profound hypoxemia (11) . Recent studies have shown that PAH represents an important risk factor for perioperative morbidity and mortality in patients undergoing non-cardiac surgery (1) (2) (3) (4) (5) (6) . The latest report of non-cardiac and non-obstetric surgery in patients with PAH was an international, prospective, three-year questionnaire-based survey of PH centers be-tween 2007 and 2010 (6) . The diseases of the patients enrolled in the study appeared to be relatively well controlled with targeted therapy for PAH, as indicated by the fact that the average RHC parameters were a mean PAP, PVR and CI of 45 mmHg, 579 dyn.s.cm -5 and 2.9 L/min/m 2 , respectively. In that study, the perioperative mortality rate was 3.5% (4/ 114) for all surgical procedures, 15% (2/13) for emergency surgeries and 2% (2/101) for elective surgeries. These mortality rates were lower than those of previous studies including patients treated up to 2003 (7-18%) (3, 4) .
Since modern therapies for PAH, such as prostacyclin, endothelin receptor antagonists and phosphodiesterase 5 inhibitors, have become widely available in recent years, better control of pulmonary hypertension can be achieved, which has likely resulted in better outcomes among PAH patients treated with elective procedures. On the other hand, emergency procedures continue to be associated with high mortality rates. One reason for the high mortality rates is that urgent procedures are performed less frequently in PH centers (75% of all surgical procedures and 57% of emergency interventions, respectively, are performed in PH centers). In the present case, the patient was successfully treated with gynecological surgery under general anesthesia. Recently, upfront combination therapy for severe PAH associated with a low CI and high PVR has achieved dramatic improvements in pulmonary hemodynamics, although no randomized control trials have been performed (12) . Since our institution specializes in pulmonary hypertension, the management of PAH, including the use of triple combination therapy, can be implemented early for well-controlled conditions to reduce the risk of complications associated with elective surgery.
In conclusion, a careful evaluation of contrast-enhanced CT and perfusion lung scans is warranted to differentiate IPAH from CTEPH in PH patients observed to have thrombi in the main pulmonary arteries. Although PAH patients constitute a high-risk population for non-cardiac and nonobstetric surgery, perioperative mortality can be reduced if a contemporary therapeutic approach, including upfront combination therapy, is used. In addition, we recommend that the perioperative management of patients be carried out in PAH centers whenever possible.
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